美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Kailera Therapeutics, Inc.

17.75

+1.217.32%

盤後：17.750.00000.00%16:10 EDT

成交量：132.39萬

成交額：2,336.09萬

市值：22.99億

市盈率：-7.87

高：18.19

開：16.75

低：16.54

收：16.54

52周最高：28.23

52周最低：16.37

股本：1.30億

流通股本：4,492.19萬

量比：1.35

換手率：2.95%

股息：- -

股息率：- -

每股收益(TTM):-2.2543

每股收益(LYR):-7,819.9811

淨資產收益率：-36.90%

總資產收益率：-22.73%

市淨率：2.06

市盈率(LYR):0.00

資料載入中...

總覽公司新聞資訊公告

Kailera Therapeutics旗下高劑量Ribupatide注射劑2b期臨床試驗完成全部入組；數據預計2027年中出爐

Kailera Therapeutics 向FDA提交Ribupatide口服活性IND申請，計劃2027年上半年啓動三期肥胖症臨床試驗

財報前瞻｜Kailera Therapeutics, Inc.管線進展提速，機構看多佔優

數據簡報-隨着小型企業不斷湧現，減肥藥的上市競爭日益白熱化

Kailera Therapeutics減肥藥在華三期試驗達主要終點，盤前股價上漲1.9%

凱萊拉制藥股價上漲，因其減肥藥在中國晚期臨床試驗中達到了主要目標

Kailera的GLP-1藥物達到了後期臨床試驗的主要目標

Kailera Therapeutics公布Hengrui Pharma口服小分子GLP-1受體激動劑HRS-7535/KAI-7535兩項III期臨床試驗積極頂線數據

Kailera Therapeutics公司推進Kai-7535在肥胖或超重人群中的全球II期臨床試驗

Parabilis Medicines計劃通過擴大規模的美國首次公開募股（IPO）實現23億美元的估值

Kailera Therapeutics 公布 HRS-7535 三期與 HRS-4729 一期試驗積極頂線數據

Kailera Therapeutics獲Leerink Partners首次覆蓋，給予「跑贏大盤」評級，目標價36美元

生物技術公司奧德賽計劃在美國首次公開募股（IPO）中尋求8.1億美元的估值

異動解讀 | 凱萊拉治療公司盤中大漲62.5%，受益於納斯達克成功上市及減肥藥市場廣闊前景

美股異動 | 減肥藥新貴Kailera Therapeutics(KLRA.US)登陸美股市場開盤暴升逾50%

BUZZ-肥胖症藥物開發商凱萊拉有望以高於發行價的價格在納斯達克上市

募資6.25億美元創五年之最減肥藥新貴Kailera Therapeutics(KLRA.US)今晚登陸納斯達克

減肥藥公司Kailera Therapeutics(KLRA.US)IPO定價14-16美元/股擬周五登陸納斯達克

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/KLRA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KLRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics, Inc.","latestPrice":17.75,"timestamp":1787688000000,"preClose":16.54,"halted":0,"volume":1323871,"hourTrading":{"tag":"盘后","latestPrice":17.75,"preClose":17.75,"latestTime":"16:10 EDT","volume":3983,"amount":70698.25,"timestamp":1787688604877,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.07315598548972194,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"盤後交易","change":1.21,"latestTime":"08-25 16:10:28 EDT","open":16.75,"high":18.19,"low":16.54,"amount":23360895.2789,"amplitude":0.099758,"askPrice":17.75,"askSize":101,"bidPrice":16.5,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":16.54,"preHourTrading":{"tag":"盘前","latestPrice":16.82,"preClose":16.54,"latestTime":"09:12 EDT","volume":142,"amount":2396.5300239999997,"timestamp":1787663555308,"change":0.28,"changeRate":0.016929,"amplitude":0.000605},"postHourTrading":{"tag":"盘后","latestPrice":17.75,"preClose":17.75,"latestTime":"16:10 EDT","volume":3983,"amount":70698.25,"timestamp":1787688604877,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.349094},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRA\",,,,,undefined,":{"symbol":"KLRA","floatShares":44921899,"roa":"-22.73%","roe":"-36.90%","lyrEps":-7819.9811,"volumeRatio":1.349094,"shares":129537300,"dividePrice":0,"high":18.19,"amplitude":0.099758,"preClose":16.54,"low":16.54,"week52Low":16.37,"pbRate":"2.06","week52High":28.2271,"institutionHeld":0,"latestPrice":17.75,"committee":-0.669421,"eps":-2.254252,"divideRate":0,"volume":1323871,"delay":0,"ttmEps":-2.254252,"open":16.75,"prevYearClose":16,"prevWeekClose":17.17,"prevMonthClose":16.94,"prevQuarterClose":22.03,"fiveDayClose":17.83,"twentyDayClose":16.74,"sixtyDayClose":22.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"KLRA","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"盤後","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-1.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783656000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRA","date":"2026-08-24","current":-7.936114,"percent":1,"low":-21.871461,"twenty":-19.582567,"median":-16.636224,"eighty":-11.274789,"high":-7.618086,"avg":-15.350689,"sd":4.227414,"marketCap":2225981916},"quantilePoints":[{"date":"2026-04-17","current":-12.669466,"twenty":-12.511098,"median":-12.273546,"eighty":-12.035993,"marketCap":1887180368},{"date":"2026-04-24","current":-20.824025,"twenty":-20.917019,"median":-20.433783,"eighty":-14.17085,"marketCap":3101842710},{"date":"2026-05-01","current":-21.741015,"twenty":-21.413894,"median":-20.305085,"eighty":-18.829635,"marketCap":3238432850},{"date":"2026-05-08","current":-19.540824,"twenty":-21.576784,"median":-20.824025,"eighty":-19.524523,"marketCap":2910703445},{"date":"2026-05-15","current":-18.697273,"twenty":-21.521865,"median":-20.058623,"eighty":-18.676401,"marketCap":2785052251},{"date":"2026-05-22","current":-18.332024,"twenty":-21.403595,"median":-19.540824,"eighty":-18.304195,"marketCap":2730646579},{"date":"2026-05-29","current":-19.949555,"twenty":-21.097481,"median":-19.520448,"eighty":-18.332024,"marketCap":2971585983},{"date":"2026-06-05","current":-18.253756,"twenty":-20.940268,"median":-19.530636,"eighty":-18.332024,"marketCap":2718988220},{"date":"2026-06-12","current":-16.992777,"twenty":-20.824025,"median":-19.392985,"eighty":-17.13192,"marketCap":2531159115},{"date":"2026-06-18","current":-16.636224,"twenty":-20.511831,"median":-18.758148,"eighty":-17.050173,"marketCap":2478048816},{"date":"2026-06-26","current":-12.75669,"twenty":-20.227867,"median":-18.684228,"eighty":-17.050173,"marketCap":2676825461},{"date":"2026-07-02","current":-12.855483,"twenty":-20.165517,"median":-18.622605,"eighty":-16.764931,"marketCap":2697555958},{"date":"2026-07-10","current":-12.9728,"twenty":-20.033041,"median":-18.410291,"eighty":-15.433812,"marketCap":2722173424},{"date":"2026-07-17","current":-11.311837,"twenty":-19.949555,"median":-18.314631,"eighty":-13.521103,"marketCap":2373641938},{"date":"2026-07-24","current":-10.743775,"twenty":-19.944337,"median":-17.453687,"eighty":-12.859187,"marketCap":2254441579},{"date":"2026-07-31","current":-10.527665,"twenty":-19.923466,"median":-17.13192,"eighty":-12.704356,"marketCap":2209093616},{"date":"2026-08-07","current":-11.651439,"twenty":-19.849563,"median":-17.071044,"eighty":-11.79378,"marketCap":2444903022},{"date":"2026-08-14","current":-7.973035,"twenty":-19.724778,"median":-16.992777,"eighty":-11.573639,"marketCap":2329696857},{"date":"2026-08-21","current":-7.746755,"twenty":-19.603438,"median":-16.640572,"eighty":-11.334065,"marketCap":2263578582},{"date":"2026-08-24","current":-7.618086,"twenty":-19.582567,"median":-16.636224,"eighty":-11.274789,"marketCap":2225981916}],"updateTime":1787685677563},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1180540299","title":"Kailera Therapeutics旗下高劑量Ribupatide注射劑2b期臨床試驗完成全部入組；數據預計2027年中出爐","url":"https://stock-news.laohu8.com/highlight/detail?id=1180540299","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180540299?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 04:45","pubTimestamp":1786567521,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics（股票代码：KLRA，公司全称：Kailera Therapeutics, Inc.）近日宣布，其正在进行的高剂量Ribupatide注射剂2b期临床试验已完成全部患者入组工作。这一里程碑标志着该研究迈入关键阶段。根据公司规划，相关试验数据预计将在2027年年中正式发布。Ribupatide作为一款备受关注的注射剂候选药物，此次高剂量方案的研究结果将为其后续临床开发提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198856529","title":"Kailera Therapeutics 向FDA提交Ribupatide口服活性IND申請，計劃2027年上半年啓動三期肥胖症臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1198856529","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198856529?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 04:44","pubTimestamp":1786567448,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics 公司已正式向美国食品药品监督管理局（FDA）提交了关于Ribupatide口服活性成分的研究性新药（IND）申请。与此同时，该公司规划在2027年上半年，启动针对肥胖症的三期临床试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129975436","title":"財報前瞻｜Kailera Therapeutics, Inc.管線進展提速，機構看多佔優","url":"https://stock-news.laohu8.com/highlight/detail?id=1129975436","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129975436?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 08:56","pubTimestamp":1785891370,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics, Inc.将于2026年08月12日美股盘后发布最新财报，市场关注其管线推进与费用节奏对亏损幅度与每股收益的影响。公司披露，该项目在大中华区外的权益归属Kailera，并同步推进全球II期试验，为后续多区域III期转化与注册策略铺路。综合各家覆盖结论，当前市场对Kailera的核心分歧在时间维度：管线价值的兑现速度与费用峰值出现时点。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Kailera Therapeutics, Inc.管线进展提速，机构看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649939231","title":"數據簡報-隨着小型企業不斷湧現，減肥藥的上市競爭日益白熱化","url":"https://stock-news.laohu8.com/highlight/detail?id=2649939231","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649939231?lang=zh_tw&edition=fundamental","pubTime":"2026-07-08 00:13","pubTimestamp":1783440834,"startTime":"0","endTime":"0","summary":"数据简报-随着小型企业不断涌现，减肥药的上市竞争日益白热化在第1、2和25段中补充了Kailera Therapeutics公司肥胖症药物的详细信息路透7月7日-凯莱拉制药的KLRA.O口服减肥药在中国开展的一项晚期临床试验中，帮助患者在第44周时减重 ，最高可达体重的10.9%。这两种药物目前均处于临床前试验阶段。华东制药中国华东制药公司的口服减肥候选药物HDM1002，在中国针对超重或肥胖受试者进行的一项早期研究中，使体重最多减少了6.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4T4391IA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","SG9999013999.USD","IE00B19Z3581.USD","LU2108987350.USD","LU1551013342.USD","LU1712237335.SGD","LU2112291526.USD","LU0109394709.USD","LU2089283258.USD","LU2491049909.HKD","KLRA","LU1923622614.USD","IE00BK4W5L77.USD","LU2023250330.USD","BK4592","LU1162221912.USD","LU1934455194.USD","LU1430594728.SGD","LU2125909247.SGD","LLYX","LU2237443549.SGD","LU0323591593.USD","IE00B4R5TH58.HKD","01672","LU0158827948.USD","SG9999015341.SGD","LU0306806265.USD","LU1883839398.USD","LU1720051017.SGD","LU0133085943.USD","LU2097828557.USD","SGXZ31699556.SGD","LU0353189763.USD","GB00BDT5M118.USD","BK4532","LU1037948541.HKD","LU0353189680.USD","LU0265550946.USD","LU0466842654.USD","LU0225284248.USD","IE00B3T34201.USD","LU0006306889.USD","LU0211331839.USD","LU2461242641.AUD","03692","LU0256863811.USD","PFE","IE0004445015.USD","SG9999015978.USD","LU0417517546.SGD","LU0820561909.HKD","SG9999015358.SGD","LU2746668974.SGD","LU0683600562.USD","AZNH","LU1035775433.USD","LU0079474960.USD","SG9999015945.SGD","LU2552382132.HKD","SG9999003800.SGD","PPH","LU1280957306.USD","LU2552382058.USD","LU2750360997.AUD","LU1868836914.USD","MEDX","IE00BFSS7M15.SGD","LU1201861249.SGD","LU1291159041.SGD","LU2237443895.HKD","LU2360106947.USD","LU1868837300.USD","LU2596442595.SGD","SG9999011175.SGD","LU1069347547.HKD","LU2456880835.USD","FTXH","LU0321505439.SGD","LU0225771236.USD","LU2357305700.SGD","LU2023250843.SGD","LU0114720955.EUR","LU1969619763.USD","IE00BLSP4452.SGD","PJP","LU2106854487.HKD","LU0672654240.SGD","LU0198837287.USD","IHE","IE0002270589.USD","LU2111349929.HKD","VHT","LLII","LU2471134879.HKD","LU2471134796.USD","THNR","LU2360032135.SGD","IE00BJLML261.HKD","LU1232071149.USD","SG9999014914.USD","IE00BSNM7G36.USD","LU0942090050.USD","LU1093756168.USD","LU0266013472.USD","LU2242644610.SGD","IE00BLSP4239.USD","LU1571399168.USD","BK4007","LU1934455863.HKD","BK4139","LU0061475181.USD","LU1093756325.SGD","PAWZ","SGXZ57979304.SGD","LU0965509283.SGD","LU0265550359.USD","LU2265009873.SGD","LU2237443465.HKD","LU2417539215.USD","SG9999014880.SGD","LU2491050071.SGD","BK1589","LU0868494708.USD","LU2271345857.HKD","LU0289739699.SGD","IE0009355771.USD","BK4599","LU0786609619.USD","LU1814569148.SGD","LU1267930730.SGD","01801","LU2023250504.SGD","LU1699723380.USD","LU0154236417.USD","LU2168564149.EUR","LU0345770308.USD","LU0861579265.USD","BK4568","LU1941712264.USD","LU0943347566.SGD","LU0029864427.USD","LU0882574139.USD","LU0985481810.HKD","LU0965508806.USD","BK1161","LU0158827781.USD","JDOC","LU0210536198.USD","LU1066051225.USD","SG9999014906.USD","IE00B7KXQ091.USD","SG9999014567.USD","LU1929549753.HKD","LU0640476718.USD","VKTX","SG9999014559.SGD","LU1037948897.HKD","BK4550","IE0004445239.USD","IE00BWXC8680.SGD","LU0456855351.SGD","LU0965509101.SGD","LU2236285917.USD","LU2491050154.USD","LU2896262040.SGD","LU0130102774.USD","LU0225283273.USD","LU1061106388.HKD","BK4559","LU1804176565.USD","LU2328871848.SGD","LU1057294990.SGD","LU0208291251.USD","LU2756315664.SGD","LU0238689110.USD","IE00B4JS1V06.HKD","SG9999018857.SGD","HRTS","LU0130517989.USD","SG9999001176.USD","SGXZ99366536.SGD","LU2237443382.USD","ELIL","BK4534","LU0648001328.SGD","LU1551013425.SGD","LU0889565916.HKD","LU2023251221.USD","LU0868494617.USD","LU2433249047.HKD","LU1323610961.USD","IE00B19Z3B42.SGD","LU1983299246.USD","LU0096364046.USD","LU0320765992.SGD","LU0256863902.USD","LU1116320901.HKD","SGXZ51526630.SGD","LU0310800379.SGD","LU2264538146.SGD","ELIS","NVOX","LU2028103732.USD","LU0203347892.USD","MEDI","LU0980610538.SGD","LU1267930573.SGD","LLY","LU0820562030.AUD","SG9999018865.SGD","LU2237443622.USD","CURE","NVO","GPCR","LU2097828474.EUR","LU2087625088.SGD","LU0320765059.SGD","LU0203201768.USD","LU1941712348.USD","IE00BJJMRY28.SGD","SG9999002232.USD","LU0882574055.USD","GDOC","IXJ","LU0385154629.USD","RXL","SGXZ81514606.USD","LU2602419157.SGD","LU0689472784.USD","SG9999017495.SGD","LU0708995401.HKD","LU0477156953.USD","LU1035773651.USD","LU1127390331.HKD","IE00BFSS8Q28.SGD","LU2237438978.USD","LU2361045086.USD","LU1066053197.SGD","LU0203202063.USD","LU1934455277.USD","IE00B1BXHZ80.USD","IE0001KFT4U8.USD","LU0965509010.AUD","LU2746668461.USD","LU0321505868.SGD","BK1515","LU1116320737.USD","LU2213496289.HKD","SG9999014575.USD","LU2168564495.EUR","LU0106261372.USD","LU0985320562.USD","CANC","IE00BZ1G4Q59.USD","LU0964807845.USD","BK1574","LU0128525929.USD","NVOH","SG9999002224.SGD","AZN","IE00BKDWB100.SGD","BK4581","LU0097036916.USD","IE00BJJMRX11.SGD","SG9999015986.USD","SG9999001176.SGD","BK1583","IYH","LU0471298777.SGD","LU0122379950.USD","LU0471298694.HKD","LU0354030438.USD","LU0320765646.SGD","LLYZ","IE00B1XK9C88.USD","LU0320765489.SGD","LU1064131342.USD","LU0094547139.USD","LU2462157665.USD","LU1585245621.USD","LU1145028129.USD","LU1917777945.USD","IE00BKVL7J92.USD","LU1066051811.HKD","LU0823434740.USD","LU1989772840.SGD","LU2361044865.SGD","IE00BFTCPJ56.SGD","LU0455707207.USD","LU0432979614.USD","LU0859254822.USD","FHLC","OZEM","SG9999001440.SGD","IE00BBT3K403.USD","LU1894683348.USD","LU2125909593.SGD","LU2089984988.USD","LU0787776722.HKD","LU2125154935.USD","BK1191","LU2471134952.CNY","SG9999014898.SGD","BMED","MRK","LU0098860793.USD","IE00BN29S564.USD","IE00BKPKM429.USD","SG9999015952.SGD","LU1548497426.USD","LU1894683264.USD","IE00BK4W5M84.HKD","LU1989771016.USD","LU2089284900.SGD","LU2357627491.SGD","XLV","LU1868836757.USD","LU0170899867.USD","BK4588","LU0354030511.USD","LU2097828631.EUR","LU1623119135.USD","LU1366192091.USD","LU0820561818.USD","LU0823434583.USD","BK4585","BK4516","LU2168563687.JPY","LU1868837136.USD","LU0234572021.USD","LU2552382215.SGD","IE0002141913.USD","HK0000165453.HKD","IE00BJJMRZ35.SGD","LU2168564065.EUR","LU2471134523.USD","LU2488822045.USD","LU1988902786.USD","WDNA","LU2361044949.HKD","LU0316494557.USD","LU1989772923.USD","KURE","LU0345770993.USD","LU0203345920.USD","SG9999014542.SGD","IE00B775H168.HKD","LU2168564222.USD","BK4533","LU2063271972.USD","LU1829250122.USD","IE00B2B36J28.USD","LU2324357040.USD","LU0306807586.USD","LU0058720904.USD","LU2756315318.SGD","IE00BN8TJ469.HKD","LU0502904849.HKD","AGNG","LU2097828714.EUR","IE000M9KFDE8.USD","LU2237443978.SGD","LU2468319806.SGD","LU0708994859.HKD","ILDR","LU1023059063.AUD","LU2097828805.USD","LU1974910355.USD","LU0823416689.USD","LU2211815571.USD","IE00BJT1NW94.SGD","LU1066051498.USD","IE0005OL40V9.USD","LU2125154778.USD","LU0070302665.USD","LU1720051108.HKD","LU1069344957.HKD","LU2750360641.GBP","LU1629891620.HKD","LU0109391861.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152571405","title":"Kailera Therapeutics減肥藥在華三期試驗達主要終點，盤前股價上漲1.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152571405","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152571405?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:37","pubTimestamp":1783424267,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics, Inc. (KLRA)的股价在盘前交易中上涨了1.9%。此前，该公司宣布其研发的一款减肥药物在中国进行的后期临床试验中达到了主要终点。这一积极进展增强了市场对其药物开发前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984035","title":"凱萊拉制藥股價上漲，因其減肥藥在中國晚期臨床試驗中達到了主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984035","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649984035?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:33","pubTimestamp":1783424019,"startTime":"0","endTime":"0","summary":"BUZZ-凯莱拉制药股价上涨，因其减肥药在中国晚期临床试验中达到了主要目标7月7日-** Kailera Therapeutics（KLRA.O）股价在盘前交易中上涨1.9%，至23.7美元** 这家药物研发公司表示，其 (link) 旗下针对糖尿病和肥胖症患者的实验性口服减肥药KAI-7535，在中国开展的两项晚期临床试验中达到了主要目标** 这些研究评估了口服小分子GLP-1受体激动剂HRS-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4T4390XY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089283258.USD","IE00B2B36J28.USD","LU0499090636.EUR","LU0047473722.SGD","LU0575583348.USD","LU2108987350.USD","LU0976567544.SGD","LU0077335932.USD","SUHJY","LU0889565080.SGD","LU0345777147.USD","LU2357627491.SGD","IE00BJJMRZ35.SGD","80016","KLRA","LU0889566641.SGD","LU0949170772.SGD","03145","LU0128525929.USD","LU1153584641.USD","SG9999001176.USD","LU0964806797.USD","LU2237443895.HKD","03165","LU1814569148.SGD","LU1196032939.SGD","LU0827474353.SGD","LU0997586515.USD","SG9999002463.SGD","LU0882574055.USD","LU0310800965.SGD","LU2088748293.HKD","LU0390134368.USD","LU0266013472.USD","LU0784385170.HKD","LU1880407215.USD","LU2279689827.SGD","OZEM","LU0792757196.USD","LU2237443622.USD","AZN.UK","03121","LU0969580561.USD","LU1015430645.USD","IE00B4R5TH58.HKD","LU0158827948.USD","LU0229494975.USD","00016","LU1989772923.USD","LU0997586432.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649810709","title":"Kailera的GLP-1藥物達到了後期臨床試驗的主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2649810709","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649810709?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:06","pubTimestamp":1783422415,"startTime":"0","endTime":"0","summary":"Kailera的GLP-1药物达到了后期临床试验的主要目标路透7月7日-凯莱拉制药公司（KLRA.O）周二表示，其用于治疗糖尿病和肥胖症患者的GLP-1药物在两项后期临床试验中达到了主要目标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nL4T4390VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174709421","title":"Kailera Therapeutics公布Hengrui Pharma口服小分子GLP-1受體激動劑HRS-7535/KAI-7535兩項III期臨床試驗積極頂線數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1174709421","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174709421?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:05","pubTimestamp":1783422302,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics公司宣布，其合作伙伴Hengrui Pharma研发的口服小分子GLP-1受体激动剂HRS-7535在两项III期临床试验中取得了积极的顶线结果。作为一款口服制剂，HRS-7535/KAI-7535若成功上市，有望为患者提供比现有注射疗法更为便捷的用药选择。GLP-1受体激动剂是当前代谢疾病治疗领域的热点，主要应用于2型糖尿病和肥胖症的管理。此次公布的积极数据，进一步验证了该靶点及口服给药途径的可行性，为相关疾病的治疗格局增添了新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134385043","title":"Kailera Therapeutics公司推進Kai-7535在肥胖或超重人群中的全球II期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1134385043","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134385043?lang=zh_tw&edition=fundamental","pubTime":"2026-07-07 19:04","pubTimestamp":1783422285,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics公司正推动其候选药物Kai-7535，在全球范围内针对肥胖或超重人群展开一项关键的II期临床试验。这项研究标志着该公司在代谢疾病治疗领域迈出了重要一步，旨在评估该药物的安全性与有效性。随着全球肥胖问题日益严峻，此类创新疗法的进展备受关注，有望为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OZEM","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642546907","title":"Parabilis Medicines計劃通過擴大規模的美國首次公開募股（IPO）實現23億美元的估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2642546907","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642546907?lang=zh_tw&edition=fundamental","pubTime":"2026-06-09 18:19","pubTimestamp":1781000373,"startTime":"0","endTime":"0","summary":"更新版 3-Parabilis Medicines计划通过扩大规模的美国首次公开募股实现23亿美元的估值第4-5段和第9段补充了分析师评论及背景信息。路透6月9日 - 随着生物技术公司首次公开募股热潮持续升温，药物开发商Parabilis Medicines计划通过在美国扩大规模的首次公开募股，将公司估值提升至近23亿美元。Parabilis上月与制药公司Regeneron Pharmaceuticals REGN.O 达成合作协议，据  报道，该公司有望通过开发针对难治性疾病的新疗法获得最高22亿美元的里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nL4S42H0RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1883839398.USD","IE00B7SZLL34.SGD","LU1894683264.USD","LU0130518102.USD","LU1974910355.USD","LU2362541513.USD","LU2089984988.USD","LU0052756011.USD","LU1366192091.USD","LU0314106906.USD","BK4553","LU1267930227.SGD","MANE","LU0289739699.SGD","LU1917777945.USD","BAC","BK4581","REGN","LU0203345920.USD","LU0203347892.USD","LU2023250504.SGD","LU2133065610.SGD","LU0823434740.USD","LU0306806265.USD","IE0001KFT4U8.USD","IE00BKVL7J92.USD","LU0980610538.SGD","LU1201861249.SGD","BK4207","IE00BFXG1179.USD","IE00BLSP4239.USD","BK4127","LU0310800965.SGD","LU0208291251.USD","LU0321505439.SGD","MNSH","LU0130103400.USD","IE0034235188.USD","BK4504","IE00B1BXHZ80.USD","IE00BZ1G4Q59.USD","KLRA","EVR","LU0234572021.USD","LU1506573853.SGD","LU0683600562.USD","LU2237438978.USD","LU2468319806.SGD","LU1363072403.SGD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141920352","title":"Kailera Therapeutics 公布 HRS-7535 三期與 HRS-4729 一期試驗積極頂線數據","url":"https://stock-news.laohu8.com/highlight/detail?id=1141920352","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141920352?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 04:08","pubTimestamp":1779826103,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics 宣布，其候选药物 HRS-7535 的三期临床试验以及 HRS-4729 的一期临床试验均取得了积极的顶线数据结果。这一进展标志着公司在相关治疗领域的研发取得了重要突破，为后续的临床开发与监管申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195378546","title":"Kailera Therapeutics獲Leerink Partners首次覆蓋，給予「跑贏大盤」評級，目標價36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195378546","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195378546?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 18:11","pubTimestamp":1778580703,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布，对生物制药公司Kailera Therapeutics启动研究覆盖。该机构给予该公司股票“跑赢大盘”的初始评级，并设定了每股36美元的目标价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632493274","title":"生物技術公司奧德賽計劃在美國首次公開募股（IPO）中尋求8.1億美元的估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2632493274","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632493274?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 18:48","pubTimestamp":1777891733,"startTime":"0","endTime":"0","summary":"更新版 2-生物技术公司奥德赛计划在美国首次公开募股中寻求8.1亿美元的估值全文补充了细节。路透5月4日 - 生物制药公司奥德赛治疗周一表示，随着投资者对药物开发商的热情高涨，该公司计划在美国首次公开募股中寻求高达8.099亿美元的估值。近几周，美国IPO市场强势反弹，为未来数月上市热潮奠定了基础。该公司计划在纳斯达克上市，股票代码为“ODTX”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL4T41H0OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250330.USD","LU2097344357.USD","NVDX","NVDW","SG9999018865.SGD","LU0354030511.USD","NVD3.UK","LU2111349929.HKD","LU0345770308.USD","KLRA","BK4527","NVDL","BK4598","NVDO","NVDS","SNVD.UK","NVIW.SI","ALMR","DIPS","NVDD","NVDG","IE00BDRTCR15.USD","LU2168563687.JPY","LU0211328371.USD","2NVD.UK","LU2326559502.SGD","NVDU","NVDQ","NVDB","LU0345769128.USD","NVDS.UK","HK0000304805.HKD","NVII","LU0466842654.USD","LU0174119429.USD","NVDA","3NVD.UK","XE","ANV","LU1645745479.HKD","LU0069063385.USD","LU1280957306.USD","NVD","NVDY","IE0009356076.USD","LU2430703251.USD","NVD2.UK","SG9999000418.SGD","SG9999015952.SGD","LU1116320901.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136289592","title":"異動解讀 | 凱萊拉治療公司盤中大漲62.5%，受益於納斯達克成功上市及減肥藥市場廣闊前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1136289592","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136289592?lang=zh_tw&edition=fundamental","pubTime":"2026-04-18 01:27","pubTimestamp":1776446849,"startTime":"0","endTime":"0","summary":"凯莱拉治疗公司今日盘中股价大幅上涨62.50%，引起了市场的广泛关注。此次股价大涨与公司成功登陆纳斯达克密切相关。消息显示，凯莱拉治疗公司首次公开募股以每股16美元的价格发行，而市场预期其开盘价将达到32美元，远高于发行价，这反映了投资者对公司的高度认可和强烈兴趣。凯莱拉治疗公司的主要候选产品ribupatide作为一种每周注射一次的GLP-1药物，目前正处于后期试验阶段，这进一步增强了市场对其未来商业化前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628578522","title":"美股異動 | 減肥藥新貴Kailera Therapeutics(KLRA.US)登陸美股市場 開盤暴升逾50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628578522","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628578522?lang=zh_tw&edition=fundamental","pubTime":"2026-04-18 00:00","pubTimestamp":1776441606,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周五，减肥药新贵Kailera Therapeutics(KLRA.US)登陆美股市场，开盘暴涨超50%，报24.1美元，IPO价格为16美元。该公司创下2021年以来美国生物科技领域规模最大的IPO纪录。Kailera成立于2024年，是一家处于临床后期的生物科技公司，正在开发四种基于GLP-1的减肥药物，其中包括一款每周注射一次的药物和一款每日口服一次的药片，目前均已进入后期临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","KLRA","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628423202","title":"BUZZ-肥胖症藥物開發商凱萊拉有望以高於發行價的價格在納斯達克上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2628423202","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628423202?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 22:16","pubTimestamp":1776435384,"startTime":"0","endTime":"0","summary":"** 减肥药开发商Kailera Therapeutics KLRA.O在纳斯达克首次上市的开盘价有望高于发行价** 最近表示股票开盘价为每股32美元，而发行价为16美元** 总部位于马萨诸塞州沃尔瑟姆市的KLRA在首次公开募股中以每股14-16美元的最高价出售了3,910万股股票 ，募集资金6.25亿美元。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL4S41018P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000M9KFDE8.USD","BK4585","IE0002270589.USD","SG9999001176.USD","SGXZ57979304.SGD","LU0058720904.USD","SG9999002224.SGD","LU0234572021.USD","LU1894683348.USD","LU0170899867.USD","LU0306806265.USD","IE00B19Z3581.USD","BK4592","LU1066051498.USD","IE00BBT3K403.USD","SG9999002232.USD","SG9999013999.USD","LU0321505868.SGD","LU1894683264.USD","BK4534","IE00BLSP4452.SGD","LU0122379950.USD","BK4127","BK4533","BK4588","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0225771236.USD","LU0868494617.USD","LU0456855351.SGD","BK4581","BK4207","KLRA","LU0225284248.USD","LU0289739699.SGD","LU0306807586.USD","LU1057294990.SGD","LU1883839398.USD","SG9999001176.SGD","SG9999011175.SGD","LU0985481810.HKD","BK4007","BK4550","BK4568","IE00BLSP4239.USD","BK4599","LU1066053197.SGD","LU1023059063.AUD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221198","title":"募資6.25億美元創五年之最 減肥藥新貴Kailera Therapeutics(KLRA.US)今晚登陸納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221198","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628221198?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 11:33","pubTimestamp":1776396818,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于肥胖症治疗的临床阶段生物科技公司Kailera Therapeutics Inc.通过扩大首次公开发行规模，成功募资6.25亿美元，创下2021年以来美国生物科技领域规模最大的IPO纪录。根据周四发布的一份声明，Kailera以每股16美元的价格出售了约3900万股股票。包括贝恩资本旗下Bain Capital Private Equity、Bain Capital Life Sciences和卡塔尔投资局在内的现有股东已表示，有意按IPO价格合计购买最多2.25亿美元的公司股票。此次IPO之前，Kailera已于去年10月通过B轮融资募资6亿美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","QQQE","JEPQ","BK4007","GPIQ","NVIW.SI","QLD","QQQJ","TQQQ","QQQM","TQQY","KLRA","QQQ","QQQA","PSQ","SQQQ","BK4139","FTEC","BK4539","MNQmain","QQQY","ONEQ","QID","QDTE","IYW","QYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627741817","title":"減肥藥公司Kailera Therapeutics(KLRA.US)IPO定價14-16美元/股 擬周五登陸納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2627741817","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627741817?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 15:19","pubTimestamp":1776151188,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，专注于开发治疗肥胖症注射及口服GLP-1类药物的III期阶段生物技术公司Kailera Therapeutics于周一公布其首次公开募股条款。根据计划，Kailera 预计将于本周四晚间完成最终定价，并于次日在纳斯达克交易所挂牌交易。其核心候选药物ribupatide目前正在全球开展III期临床试验，这是一种每周一次注射的GLP-1/葡萄糖依赖性促胰岛素多肽受体双重激动剂肽。Kailera Therapeutics成立于2024年，计划在纳斯达克上市，股票代码为KLRA。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVIW.SI","MNQmain","QDTE","BK1147","BK4539","QLD","KLRA","JEPQ","BK4007","QQQJ","SQQQ","QQQA","QID","TQQY","QYLG","QQQM","FTEC","TQQQ","PSQ","BK4139","QQQE","QQQY","ONEQ","QQQ","GPIQ","IYW"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}